← FDA DRUG APPROVALS

FDA ANDA · ANDA078765

FOSPHENYTOIN SODIUM

Sponsor: HIKMA FARMACEUTICA

APPLICATION
ANDA078765
TYPE
ANDA
ORIGINAL APPROVAL
2009-12-02
LATEST ACTION
2018-03-08
ROUTE
INTRAMUSCULAR, INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

FOSPHENYTOIN SODIUMPrescription
FOSPHENYTOIN SODIUM EQ 50MG PHENYTOIN NA/ML · INJECTABLE · INJECTION

Approval history

2018-03-08Labeling · Supplement 9 · standardAP
2018-03-08Labeling · Supplement 7 · standardAP
2018-03-08Labeling · Supplement 8 · standardAP
2013-08-14Labeling · Supplement 5AP
2009-12-02OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →